Skip to main content

Table 3 Physical fitness values at baseline (BL) and week-12 (W12)

From: A pilot study of brisk walking in sedentary combination antiretroviral treatment (cART)- treated patients: benefit on soluble and cell inflammatory markers

 

All

Walk

Strength-Walk

BL

W12

p

BL

W12

p

BL

W12

p

6 min Walking Test

 Distance (m)

642 (605–715)

730 (695–830)

<0.0001

620 (590–701)

700 (660–807)

<0.0001

684 (634–724)

792 (714–850)

<0.0001

 HRmean (bpm)

119 (107–132)

137 (116–152)

<0.0001

118 (107–135)

128 (116–154)

0.0003

121 (107–133)

138 (116–153)

0.004

 HRmean (%HRmax)

69 (63–75)

73 (63–75)

<0.0001

69 (59–75)

71 (63–83)

<0.0001

69 (63–75)

75 (68–79)

0.0005

 Δ[La] (mmol/L)

0.9 (0.2-2.2)

1.9 (0.5-4.1)

n.s.

0.8 (0.0-2.3)

1.2 (0.5-2.6)

n.s.

1.0 (0.6-2.1)

3.3 (0.7-4.5)

n.s.

 Δ RPE

1.0 (0–1)

0.5 (0–2)

n.s.

0.5 (0.0-2.0)

0.5 (0.0-0.2)

n.s.

1.0 (0.0-1.0)

0.5 (0.2-2.0)

n.s.

  1. Values are expressed as median (Q1-Q3). W12 values were compared to BL values by the Wilcoxon matched-pairs signed rank test
  2. HR heart rate, Δ[La ] difference in lactate blood concentration between before and after 6MWT, Δ RPE difference in Rate of Perceived Exertion between before and after 6MWT